Research programme: TNF receptor antagonists - ProSkelia
Latest Information Update: 23 May 2007
At a glance
- Originator ProSkelia
- Class
- Mechanism of Action Tumour necrosis factor inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Bone resorption
Most Recent Events
- 22 Sep 2004 ProSkelia has merged with Strakan to form ProStrakan
- 05 May 2003 Preclinical trials in Bone resorption in Europe (unspecified route)